Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference

FORT WASHINGTON, Pa., June 16, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today announced that Richard Morris, Chief Financial Officer, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 2:00 p.m. EDT at The St. Regis New York.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A replay of the webcast will be archived on Vitae's website for 90 days following the presentation.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing first-in-class, small molecule drugs for difficult-to-drug disease targets that can potentially address significant unmet medical needs, including disclosed programs in diabetes, Alzheimer's disease, autoimmune disorders, atopic dermatitis and acute coronary syndrome. This robust and growing portfolio of novel product candidates is generated internally by Contour®, Vitae's proprietary structure-based drug discovery platform.

For additional information, please visit the company's website at www.vitaepharma.com.

CONTACT: INVESTORS:
         Vitae Pharmaceuticals, Inc.
         Richard S. Morris, CPA
         Chief Financial Officer
         (215) 461-2000
         [email protected]

         Westwicke Partners
         John Woolford
         (443) 213-0506
         [email protected]

         MEDIA:
         6 Degrees PR
         Tony Plohoros
         (908) 940-0135
         [email protected]

You May Also Be Interested In

• NUTEX HEALTH OPENS WEST LITTLE ROCK EMERGENCY HOSPITAL IN ARKANSAS
• New NWEA Research Shows Algebra Timing Matters, But Readiness Matters More
• Tims China Announces Second Quarter 2026 Financial Results